Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Wuhan Ammunition Life-tech Files Hong Kong IPO Prospectus, Pioneering Methylation-Based Early Cancer Detection with Liver and Urothelial Cancer Tests

Fineline Cube Apr 8, 2026
Company Deals

Gilead Sciences to Acquire Tubulis for $3.15B Upfront, Adding Next-Generation ADCs TUB-040 and TUB-030 to Oncology Pipeline

Fineline Cube Apr 8, 2026
Company Deals

Biogen Licenses Alloy Therapeutics’ AntiClastic ASO Platform to Advance Next-Generation Antisense Therapy Research

Fineline Cube Apr 8, 2026
Company Deals

Everest Medicines to Acquire EverSea Medicines Singapore for $250M, Expanding Asia-Pacific Chronic Disease Portfolio

Fineline Cube Apr 8, 2026
Company Deals

Takeda Terminates Neuroscience Partnership with Denali, Returns Frontotemporal Dementia Candidate DNL593 for Strategic Realignment

Fineline Cube Apr 8, 2026
Policy / Regulatory

Beijing Unveils 32-Point Framework to Accelerate Healthcare Innovation, AI Integration, and Medical Device Development

Fineline Cube Apr 8, 2026
Company Drug

Joincare Pharmaceutical Receives NMPA Approval to Initiate JKN2401 Clinical Study in CRSwNP, Expanding TSLP-Targeting Biologic Development Across Respiratory Indications

Fineline Cube Apr 8, 2026
Company Drug

Haisco Pharmaceutical Secures NMPA Breakthrough Therapy Designation for HSK39004 Inhalation Powder in COPD, Following Successful Phase II Lung Function Data

Fineline Cube Apr 8, 2026
Company Deals

Touchstone Medical Partners with INSPUR to Advance Healthcare AI and Medical Robots

Fineline Cube Jan 6, 2026

Touchstone International Medical Science Co., Ltd. (SHA: 688013) announced a strategic partnership with INSPUR Co.,...

Company Deals Drug

Yifan Pharmaceutical Licenses ACT001 for SCLC Brain Metastases Across 12 Asian Markets

Fineline Cube Jan 6, 2026

Yifan Pharmaceutical Co., Ltd. (SHE: 002019) announced exclusive commercial cooperation and cornerstone investment agreements with...

Company Drug

Humanwell Healthcare’s HW221043 Receives NMPA Approval for Advanced Solid Tumor Trials

Fineline Cube Jan 6, 2026

Humanwell Healthcare (Group) Co., Ltd. (SHA: 600079) announced that its independently developed HW221043 tablets have...

Company Deals

Bio-Sincerity Partners with Xellar on AI Organoid Chip Drug Discovery Platform

Fineline Cube Jan 6, 2026

Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. (SHE: 301096) and Xellar Biosystems announced a strategic cooperation agreement...

Company Drug

Frontier Biotech’s FB7013 Wins NMPA IND for MASP‑2 siRNA in IgA Nephropathy

Fineline Cube Jan 5, 2026

Frontier Biotechnologies Inc. (SHA: 688221) announced that it has submitted an Investigational New Drug (IND)...

Company Deals R&D

Insilico Medicine Partners with Servier on $888 Million AI Oncology Deal

Fineline Cube Jan 5, 2026

Insilico Medicine (HKG: 3696) announced a multi‑year R&D collaboration with Servier to identify and develop...

Company Drug

Kelun-Biotech’s sac-TMT Wins Breakthrough Therapy Designation for First‑Line NSCLC

Fineline Cube Jan 5, 2026

Sichuan Kelun‑Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced that sacituzumab tirumotecan (sac‑TMT, SKB264/MK‑2870), its TROP2‑directed...

Company Deals

Kangtai Biological Co‑founds Beijing Laboratory to Advance Synthetic Immunology and Vaccine Manufacturing

Fineline Cube Jan 5, 2026

Shenzhen Kangtai Biological Products Co., Ltd. (SHE: 300601) announced that its wholly‑owned subsidiary Minhai Biotechnology...

Company Drug

Kelun-Biotech’s ITGB6 ADC SKB105 Wins NMPA IND Approval

Fineline Cube Jan 5, 2026

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced that its Investigational New Drug (IND) application...

Company Deals

Huadong Medicine Licenses MC2’s PAD‑Based Biomee Skincare for Greater China

Fineline Cube Jan 5, 2026

Huadong Medicine Co., Ltd (SHE: 000963) announced an agreement with MC2 Therapeutics Ltd. (a wholly‑owned...

Policy / Regulatory

CMS Unveils BALANCE Model to Expand GLP-1 Access for Medicare/Medicaid

Fineline Cube Jan 5, 2026

The U.S. Centers for Medicare & Medicaid Services (CMS) unveiled the BALANCE Model (Better Approaches...

Company Drug

GenEditBio’s GEB-101 Wins FDA IND Approval as World’s First Corneal Gene Therapy

Fineline Cube Jan 5, 2026

GenEditBio announced that GEB-101, its self‑developed in vivo genome editing investigational drug, has received Investigational...

Company Drug

Merck’s Winrevair Wins China NMPA Approval for Pulmonary Arterial Hypertension

Fineline Cube Jan 5, 2026

Merck Sharp & Dohme Inc. (MSD, NYSE: MRK) announced that Winrevair (sotatercept for injection), the world’s...

Company Deals

Aspen Holdings Sells Asia‑Pacific Business to BGH Capital for AUD 2.37 Billion

Fineline Cube Jan 4, 2026

Aspen Holdings announced a binding agreement for its wholly‑owned subsidiary Aspen Global Incorporated (AGI) to...

Company Deals Drug

China Approves Record 76 Innovative Drugs in 2025 as Out‑Licensing Hits $130 Billion

Fineline Cube Jan 4, 2026

The National Medical Products Administration (NMPA) announced that China approved 76 innovative drugs for marketing...

Company Drug

China Supreme Court Upholds Novo Nordisk Semaglutide Patent Validity

Fineline Cube Jan 4, 2026

Novo Nordisk (NYSE: NVO) announced that China’s Supreme People’s Court upheld the Beijing IP Court ruling,...

Company Deals

Insilico Medicine and Hisun Pharma Nominate PCC in 8 Months via AI Platform

Fineline Cube Jan 4, 2026

Insilico Medicine (HKG: 3696) and Hisun Pharmaceutical (SHA: 600267) announced the nomination of a Preclinical...

Company Drug

Genmab Discontinues Acasunlimab to Focus on Late‑Stage Portfolio

Fineline Cube Jan 4, 2026

Genmab A/S (NASDAQ: GMAB) announced it will discontinue clinical development of acasunlimab, a PD‑L1 x...

Policy / Regulatory

NHC Releases Fourth Batch Generic Drugs Catalogue, Prioritizing Innovation and Fertility Support

Fineline Cube Jan 4, 2026

The National Health Commission (NHC) released the Fourth Batch of the National Catalogue of Encouraged...

Company Drug

Tarlatamab Enters China via Hainan Pilot Zone as First SCLC Immunotherapy

Fineline Cube Jan 4, 2026

Ruijin Hospital Hainan Boao Research Hospital (Ruijin Hainan Hospital) successfully introduced Tarlatamab for Injection, making...

Posts pagination

1 … 43 44 45 … 647

Recent updates

  • Wuhan Ammunition Life-tech Files Hong Kong IPO Prospectus, Pioneering Methylation-Based Early Cancer Detection with Liver and Urothelial Cancer Tests
  • Joincare Pharmaceutical Receives NMPA Approval to Initiate JKN2401 Clinical Study in CRSwNP, Expanding TSLP-Targeting Biologic Development Across Respiratory Indications
  • Haisco Pharmaceutical Secures NMPA Breakthrough Therapy Designation for HSK39004 Inhalation Powder in COPD, Following Successful Phase II Lung Function Data
  • Insilico Medicine Advances AI-Discovered NR3C1 Antagonist ISM6200 into Clinical Development for Ovarian Cancer and Cortisol-Excess Disorders
  • Sanofi’s Bispecific Nanobody Lunsekimig Achieves Primary Endpoints in Asthma and CRSwNP Phase II Studies, Shows Mixed Results in Atopic Dermatitis
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Wuhan Ammunition Life-tech Files Hong Kong IPO Prospectus, Pioneering Methylation-Based Early Cancer Detection with Liver and Urothelial Cancer Tests

Company Drug

Joincare Pharmaceutical Receives NMPA Approval to Initiate JKN2401 Clinical Study in CRSwNP, Expanding TSLP-Targeting Biologic Development Across Respiratory Indications

Company Drug

Haisco Pharmaceutical Secures NMPA Breakthrough Therapy Designation for HSK39004 Inhalation Powder in COPD, Following Successful Phase II Lung Function Data

Others

Insilico Medicine Advances AI-Discovered NR3C1 Antagonist ISM6200 into Clinical Development for Ovarian Cancer and Cortisol-Excess Disorders

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.